DXC014

Phase 1Small molecule

HHangzhou DAC Biotechnology Co., Ltd.

DXC014 is one of 52 small molecule programs targeting Small Cell Lung Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small Cell Lung CancerRecruiting

Small Cell Lung CancerPhase 1

Recruiting

Competition

Competitive Landscape

154 competitors in Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

33 2

Imfinzi

AstraZeneca

Phase 3

30 3

Tecentriq

Roche

Phase 3

27 4

Camptosar

Pfizer

Phase 3

26 5

Keytruda

Merck & Co.

Phase 3

20 6

Vepesid

Avastin

16 8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

96 9

Opdivo

Tarlatamab-Dznl

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1Recruiting

Small Cell Lung Cancer

NCT07177937

Clinical

Trials by Indication[1]

Small Cell Lung Cancer1 trial

An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of DXC014 for Injection in Patients With Advanced Solid Tumors.

Recruiting·HHangzhou DAC Biotechnology Co., Ltd.·Phase 1·NCT07177937·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DXC014. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DXC014 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DXC014. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hangzhou DAC Biotechnology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HHangzhou DAC Biotechnology Co., Ltd.

DXC014

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News